Libera Bio aims to change cancer therapy by enabling biologics to cross the cell membrane and reach “untreatable” intracellular targets – the “Holy Grail” of oncology.
Libera Bio leverages its unique patented nanotechnology to retain and protect biologics (e.g. antibodies) in the bloodstream after intravenous administration and to deliver them intracellularly to the tumor and metastatic cells.
Libera Bio seeks to maximize the use of its technology with oncology biopharmaceutical partners to offer patients innovative new cancer treatments based on intracellular delivery of biologics.